ALLOGRAFTING WITH NON-MYELOABLATIVE CONDITIONING FOLLOWING CYTODUCTIVE AUTOGRFTS FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

David G. Maloney, M.D., Ph.D.1,2, Arthur J. Molina, M.D.1,2, Firoozeh Sahebi, M.D.4, Keith E. Stockerl-Goldstein, M.D.5, Brenda M. Sandmaier, M.D.1,2, William Bensinger, M.D.1,2, Barry Storer, Ph.D.1,2, Ute Hegenbart, M.D.7, George Somlo, M.D.4, Thomas Chauncey, M.D., Ph.D.1,2,3, Benedetto Bruno, M.D.8, Frederick R. Appelbaum, M.D.1,2, Karl G. Blume, M.D.5, Stephen J. Forman, M.D.4, Peter McSweeney, M.D.6, and Rainer Storb, M.D.1,2

1Fred Hutchinson Cancer Research Center, 2University of Washington, and 3VA Medical Center, Seattle, WA; 4City of Hope National Medical Center, Duarte CA; 5Stanford University Medical Center, Stanford, CA; 6University of Colorado, Denver, CO; 7University of Leipzig, Leipzig, Germany, and 8University of Torino, Torino, Italy.

Short Title for Running Head: Auto/Allo Transplants for Myeloma

Supported in part by NIH grants CA78902, CA18221, CA15704, and CA49605.

Address correspondence to: David G. Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
1100 Fairview Ave North, D1-100
PO Box 19024
Seattle, WA 98109-1024
Phone: 206-667-5616
Fax: 206-667-6124
Email: dmaloney@fhcrc.org

Word Counts: Abstract Only: 256 Text: 4389

Scientific Heading: Transplantation
ABSTRACT

The full potential of a graft-versus-myeloma effect after allogeneic hematopoietic cell transplantation (HCT) for patients with multiple myeloma (MM) has not been realized because of excessive early transplant-related mortality (TRM) with conventional HCT. Autologous HCTs have been characterized by almost universal disease recurrences. The current trial combined autologous HCT with subsequent non-myeloablative allogeneic HCT to maintain the benefits of both approaches with acceptable toxicity. Fifty-four patients, 52 years (median, range 29-71) old, with previously treated stage II or III MM (52% refractory or relapsed disease) were given melphalan 200 mg/m² and autologous HCT. Regimen-related toxicities after autologous HCT were moderate with a median of 6 days of neutropenia, 7 days of hospitalization, and one death from infection. Forty to 229 days later (median 62), 52 patients received a single fraction dose of 2 Gy total body irradiation and HCT from HLA-identical siblings with postgrafting immunosuppression with mycophenolate mofetil (MMF) and cyclosporine (CSP). Patients experienced medians of 0 days of hospitalization, neutropenia, and thrombocytopenia. Sustained engraftment was uniform. With a median follow-up of 552 days after allografting, overall survival is 78%. One patient (2%) died before day-100 from disease progression. Thirty-eight percent of patients developed acute GVHD (grade II in all but 4 cases) and 46% chronic GVHD requiring therapy. Tumor responses occurred slowly. Thus far, 57% of patients have achieved complete remissions and 26% partial remissions for an overall response of 83%. Despite being evaluated in elderly patients with MM, this two-step approach has reduced the acute toxicities of allogeneic HCT while achieving potent anti-tumor activities.

Key Words: Non-myeloablative transplantation; allogeneic transplantation; autologous transplantation; multiple myeloma therapy; graft-vs.-host disease; cyclosporine; mycophenolate mofetil.
INTRODUCTION

High-dose therapy with autologous hematopoietic cell transplant (HCT) for advanced-stage myeloma in patients less than 65 years of age has survival advantages compared to conventional therapy. In the Intergroupe Francais du Myélome (IFM) 90 trial, the CR rate was higher and the 7-year event-free survival (EFS) 16% and overall survival (OS) 43% compared with 8% and 25% with conventional chemotherapy, respectively. The use of tandem autografts is also superior to standard chemotherapy and may be better than a single autograft. Recent data from the IFM94 trial, published in abstract form, comparing single Mel (140) + TBI (8 Gy) vs tandem Mel (140) followed by Mel (140) + TBI (8 Gy) in 399 patients found a similar complete remission (CR) rate of 34% vs 35% but 7-year EFS of 10% vs 20% and 7-year OS of 21% vs 42% favoring the tandem transplant arm. Despite high response rates and relatively low transplant-related mortality of <10%, however, fewer than 30% of patients remain in remission 3-7 years later. The high rate of progression/relapse following autologous HCT is due to the inability to eliminate all tumor cells from the patients and, possibly from the autografts. Purging of grafts to reduce tumor contamination has not been shown to be beneficial, and may increase the risk of infections due to removal of host immune cells. While a number of conditioning regimens have been used, melphalan at 200 mg/m² has been well tolerated, even in patients in their seventh decade of life, and has generally been accepted as the current standard.

In contrast, the use of allogeneic HCT following high-dose conditioning provides a tumor-free stem cell source and graft-vs-myeloma activity through immune responses against minor antigen differences between donor and host. Allogeneic HCT has been associated with a higher frequency of sustained molecular remissions and a lower risk of relapse. The graft-vs-myeloma activity of donor lymphocyte infusions (DLI) in patients who have relapsed after conventional allografting further demonstrates the allogeneic immune cells’ potential; however, these responses are often brief and associated with GVHD. Unfortunately, allogeneic HCT has been associated with high transplant-related mortality (20-50+% in the first 180 days) even in adults less than 55 years old, which has tempered enthusiasm with this approach and led to the early closure of the allogeneic BMT arm in the U.S. intergroup trial. Recent analysis of transplant registry data reported to the EBMT suggests that the TRM
associated with conventional allografts has decreased in the more recent cohort of patients transplanted between 1994-1998 with a TRM at 6 months of 21% compared with 38% in patients transplanted between 1983-1993. This decrease was attributed to a lower risk of fatal infections and pulmonary toxicity and was likely due to better patient selection. The 3-year survival following HCT was 55% in the later cohort compared with 35% in the earlier experience. The use of peripheral blood stem cells (PBSC) rather than BM was associated with earlier engraftment but no difference in survival or CR rates. However, it is important to note that the median age in the recent cohort was 44 with a range of 18-57 and patients were transplanted a median of 10 months from diagnosis. Thus, the advantages of allografts have been outweighed by the higher TRM compared with autografts, resulting in similar or inferior survival at 3-6 years despite the lower risk of relapse.

Recently, a new approach to allografting has been developed using non-myeloablative conditioning and novel post-transplant immunosuppression to assure engraftment and graft-vs.-tumor effects for eradication of various hematologic malignancies. In contrast to conventional high-dose allografting, a low overall transplant-related mortality of approximately 15% was observed in patients either too old or medically infirm to undergo conventional HCT. The 100-day mortality was 4.5%. Taking advantage of this new approach, we postulated that by combining cytoreduction and safety achieved with high-dose autologous HCT and graft-vs.-myeloma effects of non-myeloablative HCT from HLA-identical siblings, we could safely extend the benefits of allogeneic transplantation to older patients (age to 65) and hopefully achieve cures of multiple myeloma.

PATIENTS AND METHODS

Patients

From August 14, 1998 to June 1, 2001, 54 patients with MM were entered on treatment at the Fred Hutchinson Cancer Research Center, the University of Washington, and the Veterans Administration Hospital in Seattle, WA, the City of Hope Medical Center in Duarte, CA,
Stanford University, Stanford, CA, the University of Leipzig, Leipzig, Germany, the University of Torino, Torino, Italy, and the University of Colorado, Denver, CO. Clinical characteristics of the patients are shown in Table 1. Their median age was 52 (range 29-71) years. Seven patients were age >60, two of whom were >age 65. Eighty-seven percent of patients had stage II/III disease at diagnosis, and others had progressed to require therapy. All patients had received prior therapy for their myeloma. At the time of autografting, patients had received a median of 4 (range 4-19) cycles of prior chemotherapy, with 93% having received the vincristine, adriamycin and dexamethasone (VAD) regimen (median 4, range 2-10 cycles). Forty-eight percent of patients had received more than one treatment regimen, 8% prior radiation therapy, and 8% prior thalidomide. At the time of autologous HCT, 48% had relapsed or refractory disease from their prior therapy. Fifty-two percent had disease which was responsive to their last treatment, including 41% who had achieved partial remissions (PR), and 11% complete remissions (CR). Thirty-two percent of patients had elevated beta-two microglobulin > 2.5. Entry criteria included serum bilirubins < twice normal; left ventricular ejection fractions >40%; creatinine clearances >40 mL/min; and Karnofsky performance status >60. Patients and donors signed written informed consents on protocols approved by the institutional review boards of each participating institution.

Table 1. Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N=54</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age - median (range) yrs</td>
<td>52 (29-71)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>37</td>
<td></td>
<td>68.5%</td>
</tr>
<tr>
<td>Prior chemotherapy</td>
<td>54</td>
<td></td>
<td>100%</td>
</tr>
<tr>
<td>VAD</td>
<td>50</td>
<td></td>
<td>93%</td>
</tr>
<tr>
<td># cycles - median (range)</td>
<td>4 (2-10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>More than one regimen</td>
<td>26</td>
<td></td>
<td>48%</td>
</tr>
<tr>
<td>XRT</td>
<td>4</td>
<td></td>
<td>7.8%</td>
</tr>
<tr>
<td>Response from last therapy at time of auto HCT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>6</td>
<td></td>
<td>11%</td>
</tr>
<tr>
<td>PR</td>
<td>22</td>
<td></td>
<td>41%</td>
</tr>
<tr>
<td>Untreated relapse</td>
<td>7</td>
<td></td>
<td>13%</td>
</tr>
<tr>
<td>Refractory</td>
<td>19</td>
<td></td>
<td>35%</td>
</tr>
<tr>
<td>B2M – median (range)</td>
<td>1.94</td>
<td>(0.6-5.8)</td>
<td></td>
</tr>
<tr>
<td>B2M &gt;2.5</td>
<td>16/50</td>
<td></td>
<td>32%</td>
</tr>
<tr>
<td>Days Dx to auto – median (range)</td>
<td>282</td>
<td>(163-3629)</td>
<td></td>
</tr>
</tbody>
</table>

VAD = vincristine, adriamycin, dexamethasone, XRT = Radiation therapy, CR = Complete remission, PR = Partial remission, Dx = diagnosis.
Treatment Plan

PBSC mobilization / high-dose melphalan / autologous HCT

Unless previously cryopreserved, PBSCs (target of $5 \times 10^6$ CD34 cells/kg) were collected and cryopreserved, following cyclophosphamide, 3-4gm/m$^2$, on day +1, with or without Paclitaxel (Taxol), 250 mg/m$^2$, on day +2 and granulocyte-colony stimulating factor (G- CSF), 10 µg/kg subcutaneously, from day 3 through collection. This regimen was based on experience demonstrating more effective stem cell mobilization compared with CY/G-CSF alone. The first four patients had CD34-selected PBSCs using the CellPro CD34 cell selection device in attempts to decrease myeloma cell contamination. This was discontinued after higher risks of cytomegalovirus (CMV) and other infections were found following CD34 selection.

Melphalan, 200 mg/m$^2$, was given at least 31 days after mobilization chemotherapy via central catheter (undiluted as bolus injection or diluted with sodium chloride) over 15-20 minutes. Autologous PBSCs were thawed and infused 48 hours after melphalan. The day of PBSC infusion was designated day 0. Patients received G-CSF 5µg/kg from days 0 or 5 of autografting until neutrophil counts >1000/µL were achieved.

Donor HCT collection / non-myeloablative allografting

Upon recovery from autologous HCT (planned range of 40-120 days), patients underwent allografting. Recovery was defined as: 1) resolved mucositis and no need for IV hydration; 2) renal and hepatic function returned to entry criteria; 3) no IV antibiotics; 4) CMV antigen negative. Conditioning consisted of 2 Gy total body irradiation (TBI) at 7cGy/min by linear accelerator. Nine patients received in addition fludarabine 30 mg/m$^2$ on days –4, -3, -2. Donor PBSC were infused on day 0 after TBI. Postgrafting immunosuppression included mycophenolate mofetil (MMF), 15 mg/kg b.i.d. orally from the evening of day 0 until day +27 and cyclosporine (CSP), 6.25 mg/kg orally b.i.d. from day –1 to day +35 or 56 and then tapered. CSP trough levels were evaluated on day 3, then twice weekly and targeted to ~500 ng/mL (Abbott TDx, Abbot Park, IL) until CSP taper. In case of toxicity, CSP was adjusted. MMF doses were rounded to the nearest 250 mg.
Donors were HLA-identical siblings, 31-73 (median 50) years old (Table 2). Donor PBSC were mobilized using G-CSF, 16 µg/kg/day (day –4 to 0), with aphereses on days –1 and 0. PBSCs harvested on day –1 were stored (4°C overnight) and infused with the day 0 collection. The median numbers of CD34+ and CD3+ T-cells infused were 8.5 (range 2.0-28.0) x 10^6/kg and 3.5 (range 1.4-11.7) x 10^8/kg, respectively.

<table>
<thead>
<tr>
<th>Table 2. Characteristics and Results Following Non-Myeloablative HCT</th>
<th>N= 52 patients receiving allografts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days from Auto to Allograft, median</td>
<td>62</td>
</tr>
<tr>
<td>Donor age, median yrs</td>
<td>50</td>
</tr>
<tr>
<td>Number CD34 cells x 10^6/kg, median</td>
<td>8.5</td>
</tr>
<tr>
<td>Number CD3 cells x 10^8/kg, median</td>
<td>3.5</td>
</tr>
<tr>
<td>Granulocyte nadir, median cells/µl</td>
<td>760</td>
</tr>
<tr>
<td>Days granulocyte &lt;500/µL, median</td>
<td>0</td>
</tr>
<tr>
<td>Platelet nadir, median cells/µl</td>
<td>95,000</td>
</tr>
<tr>
<td>Days platelets &lt;20,000/µL, median</td>
<td>0</td>
</tr>
<tr>
<td>Number of platelet transfusions, median</td>
<td>0</td>
</tr>
<tr>
<td>Number RBC transfusions, median</td>
<td>0</td>
</tr>
<tr>
<td>Days hospitalized, median</td>
<td>0</td>
</tr>
</tbody>
</table>

GVHD
- Acute GVHD II-IV 20/52 38.5%
- Grade I 16/52 30.8%
- Grade III 1/52 1.9%
- Grade IV 3/52 5.8%
- Chronic GVHD 32/50 64%
- Chronic extensive GVHD 23/50 46%

GVHD= Graft-vs host disease

Supportive care
Patients received standard prophylaxis against bacterial, pneumocystis carinii, and fungal infections, and herpes simplex, and varicella-zoster virus reactivation. CMV reactivation was monitored and treated with ganciclovir.46

Analyses of chimerism and residual disease
Degrees of donor chimerism of peripheral blood T-cells and granulocytes, and unfractionated marrow were assessed at days 28, 56, 180, and 360 after allogeneic HCT using fluorescence-in-situ hybridization (FISH) in sex-mismatched pairs, and polymerase chain reaction (PCR) analyses of polymorphic microsatellite regions in sex-matched pairs.47
Disease responses were assessed using the American Bone Marrow Transplant Registry criteria with the following modifications. Complete remissions required absence of the original monoclonal proteins in serum and urine by protein electrophoreses and of clear bands on immunofixation, less than 5% plasma cells in marrow aspirates, without evidence of clonal disease by flow cytometry, and no increases in sizes or numbers of osteolytic bone lesions. Partial remissions were defined as >75% reduction in the levels of serum monoclonal protein, >90% reduction in 24-hour urinary light chain excretion, and no increases in sizes or numbers of lytic bone lesions. Patients with less than a PR, without disease progression were considered stable disease (SD). Patients were evaluated for disease once prior to autologous conditioning and once prior to nonmyeloablative conditioning to estimate the baseline level of disease activity prior to each transplant.

Endpoints
The primary purpose of the study was to reduce the day-100 mortality from the current 20-50% seen following myeloablative HCT to <20% following the tandem transplants in this older population. Secondary endpoints included engraftment and the degree of donor chimerism, response, disease-free survival and the incidence of acute and chronic GVHD. Data were analyzed as of 6/01/2002.

Donor lymphocyte infusions (DLI)
The original intent was to utilize nonmyeloablative allografting to establish mixed donor chimerism and serve as a platform for subsequent DLI to convert partial to full donor chimerism and to eliminate residual or progressive disease. As all but one patient achieved full donor chimerism, DLI was administered to only one patient for mixed chimerism with subsequent conversion to full donor chimerism. No other patients have received DLI.
RESULTS

Autologous HCT

Table 3 summarizes the outcome following high dose melphalan and autologous HCT. Patients were transplanted a median of 9 (range 5-119) months from their diagnosis of multiple myeloma.

Regimen-related toxicities, peripheral blood cell changes, transfusions and infections:
The majority of patients experienced mucositis, nausea and vomiting and diarrhea and required a median of 7 (range 0-34) days hospitalization following conditioning of high-dose melphalan.
The median days of neutrophils <500/µL and platelets <20,000/µL were 6 (range 0-17) days and 1 (range 0-36) day, respectively. Patients were transfused medians of 1 (range 0-21) unit of red blood cells (RBC) and 1 (range 0-130) unit of platelets, respectively.

Patients experienced 14 bacterial and 8 viral infections (3 CMV), and 5 patients had oral candida albicans. One patient developed CMV pneumonitis and died 31 days after CD34 selected autologous HCT.

Estimation of disease response: (Table 3). Patients were evaluated following their autografts and prior to allogeneic HCT to estimate their response to the high-dose melphalan. One patient who died from infection was not evaluable for response. Of 22 patients with responsive disease prior to the autograft, 5 achieved CR, 11 PR, and 6 had stable disease. Of 25 patients with relapsed or refractory disease prior to the autograft, none had CR, 9 had PR, 13 had stable disease and 3 had disease progression. The six patients in CR prior to the autograft remained in CR.

Allogeneic HCT

Fifty-two allografts were carried out a median of 62 (range 40-229) days after autologous HCT. One patient died prior to allografting and one patient was felt to be too ill post autograft and taken off study. Characteristics and results following allografting for the 52 patients are shown in Table 2.

Regimen-related toxicities, peripheral blood cell changes, and allogeneic engraftment:
Patients did not experience severe mucositis, diarrhea or severe nausea and vomiting. During the first 2 months, 16 (31%) patients developed transient grade II renal toxicities (likely due to
targeting high CSP levels). Transient grades II and III hepatic toxicities occurred in 7 (13%) and 5 (10%) patients, respectively. During the first 2 months, patients were hospitalized a median of 0 (range 0-37) days.

The median period of neutropenia was 0 (range 0-19) days. The median neutrophil nadir was 760 (range 100-3184) cells/µL. The median period of thrombocytopenia was 0 (range 0-1) days. The median platelet nadir was 95,000 (range 15,000-192,000) cells/µL. The median numbers of platelet and RBC transfusions within the first 60 days were 0 (0-40) and 0 (0-140), respectively. No serious hemolysis occurred in 7 ABO incompatible transplants.

All 52 patients had sustained allografts (Figure 1). On day 28, 90%, 95% and 95% of CD3+ T-cells, granulocytes, and nucleated marrow cells, respectively, were of donor origin (median values). This increased to 96-100% through day 84. One patient with 83% donor T-cell chimerism on day +28, received DLI of $10^6$ CD3 cells/kg on day +85 and subsequently evolved to 97% donor T-cell chimerism.

**Acute GVHD:** Twenty (38.5%) patients developed grade II-IV acute GVHD at a median of 58 (range 10-107) days (Figure 2). This was grade II in 16, grade III in one, and grade IV in three patients (Table 2). Fifteen patients had skin, 11 had gut, and 8 had liver involvement. GVHD responded in most patients either to resumption of CSP, MMF or treatment with
methylprednisolone, at 2 mg/kg/day with subsequent taper.

**Chronic GVHD:** Twenty-three patients (46%) developed chronic extensive GVHD requiring therapy with CSP, MMF with or without prednisone (Table 2 and Figure 2).

**Infections:** Pulmonary aspergillus infections occurred in two patients who were successfully treated with amphotericin followed byitraconazole. Ten patients developed infections with blood cultures positive for coagulase negative staph (6), and one each with Acinetobacter, serratia marcescens, pseudomonas, and listeria, and were successfully treated with appropriate antibiotics. Two patients developed urinary tract infections with staphylococcus or E-coli. Eleven of 38 patients (29%) who were CMV seropositive or had CMV seropositive donors developed CMV antigenemia and were treated with prophylactic ganciclovir. One patient had CMV colitis. One patient developed BK virus in the urine and 1 patient each developed VZV and HSV infections. Two patients were treated for Clostridium difficile following detection of toxin in the stool. Nine patients were treated for undiagnosed upper respiratory infections and one patient had parainfluenza isolated from nasopharyngeal washings.

**Disease responses:** Twenty-five of the 48 patients (52%) who were not in CR at study entry (including the two patients who did not proceed to allografting), achieved CR and 14 (29%) achieved PR with an overall response rate of 81% at a median follow-up of surviving patients of 550 (range 194-1114) days after allografting. Twenty-five (46%) are surviving in CR (Tables 2 and 3). One patient achieved CR following DLI and converted from partial to complete donor chimerism without GVHD. Nine additional patients have achieved at least PR to date, with continued regressions of disease markers. Table 3 summarizes overall responses to each portion of the trial. Of 6 patients who were in CR at the start of the trial, 1 has relapsed and 2 have died from infection or GVHD. Overall, 3 of the 31 patients with CR have had disease reoccurrence. Of 22 patients in PR (responsive disease to last therapy) at study entry, 14 achieved CR, 6 PR and 2 had stable disease. Only one patient has progressed. Thus, of the 28 patients with responsive disease (CR + PR) at the time of study entry, only 2 patients have progressed and 16 of the 28 are in continuous CR, 5 in PR and 2 continue with stable disease. Of 26 patients with
refractory or relapsed disease, 11 achieved CR, 8 PR, 2 had stable disease, and 3 disease progression. Two patients were not evaluable for response as they did not receive allografts.

<table>
<thead>
<tr>
<th>At Time of Auto (n=54)</th>
<th>Post Auto (n=54)</th>
<th>Best Post Allo (n=52)</th>
<th>Outcome, months post allo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deceased (n=12)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Month/Cause</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 CR</td>
<td>6 CR</td>
<td>6 CR</td>
<td>3/enceph, 7/GVHD</td>
</tr>
<tr>
<td>22 PR</td>
<td>5 CR</td>
<td>5 CR</td>
<td>-</td>
</tr>
<tr>
<td>11 PR</td>
<td>6 CR</td>
<td>-</td>
<td>12, 12, 13, 20, 24, 37</td>
</tr>
<tr>
<td>5 PR</td>
<td>-</td>
<td>-</td>
<td>7, 12, 13, 18, 24</td>
</tr>
<tr>
<td>6 SD</td>
<td>3 CR</td>
<td>-</td>
<td>12, 12, 13</td>
</tr>
<tr>
<td></td>
<td>1 PR</td>
<td>14/pulm.cGVHD</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>2 SD</td>
<td>-</td>
<td>9, 18</td>
</tr>
<tr>
<td>7 REL</td>
<td>0 CR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1 PR</td>
<td>1 PR</td>
<td>6/GVHD</td>
<td>-</td>
</tr>
<tr>
<td>6 SD</td>
<td>1 CR</td>
<td>37/GVHD</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>3 PR</td>
<td>14/lung Cancer</td>
<td>19, 19</td>
</tr>
<tr>
<td></td>
<td>2 PD</td>
<td>23/MM</td>
<td>19</td>
</tr>
<tr>
<td>19 REF</td>
<td>0 CR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8 PR</td>
<td>6 CR</td>
<td>-</td>
<td>12, 18, 18, 18R, 20, 31</td>
</tr>
<tr>
<td></td>
<td>2 PR</td>
<td>13/GVHD</td>
<td>13</td>
</tr>
<tr>
<td>6 SD</td>
<td>3 CR</td>
<td>-</td>
<td>18, 36, 36</td>
</tr>
<tr>
<td></td>
<td>1 PR</td>
<td>10R/GVHD</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>2 SD</td>
<td>3/GVHD</td>
<td>6</td>
</tr>
<tr>
<td>3 PD</td>
<td>1 CR</td>
<td>-</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>1 PR</td>
<td>-</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>1 PD</td>
<td>3/MM</td>
<td>-</td>
</tr>
<tr>
<td>2 NE</td>
<td>2 NE</td>
<td>CMV post auto</td>
<td>1 alive no allo</td>
</tr>
</tbody>
</table>

**Abbreviations:** CR = Complete Remission, PR = Partial Remission, PD = Progression of Disease, REF = Refractory Disease, REL = Untested Relapsed Disease, SD = Stable Disease, GVHD = Graft vs Host Disease, MM = Myeloma, R = Relapse, NE = Not Evaluable.
Attainment of CR was gradual. Two patterns are illustrated in Figure 3. Most patients had continued regression of disease following each phase of treatment. Some patients had obvious regressions of disease following the allografts that were sometimes associated with GVHD. In most patients, monoclonal bands gradually disappeared over 6 to 12 months with a median time to CR of 6 months.

**Overall and Progression Free Survivals**

With median follow-ups for surviving patients of 611 (range 257-1210) days after autologous and 550 (range 194-1114) days after allogeneic HCT, 78% (42/54) of patients are surviving (Figure 4). Twelve patients have died, one from CMV pneumonia following autologous HCT and eleven have died following allogeneic HCT. Of the eleven, three died from disease progression at day +91, 296, and 689, one died from progressive encephalopathy at day +102, three died from complications associated with grade IV acute GVHD at days +104, +136 and +138, one died from pulmonary infection associated with chronic GVHD at day +212, and 2 died with pulmonary failure (BOOP) at days 413 and 1131 post transplant, respectively. One additional patient died in CR from an unrelated malignancy, lung cancer, at day 410. The 100-day mortalities after auto and allo HCT were 2% (n=1) and 2% (n=1), respectively, with the one allogeneic recipient dying of disease progression. That patient had a 4
month delay between auto and allo HCT due to insurance issues. Estimated progression free survival for all patients at 2 years is 55% (Figure 4).

Of the 28 patients with responsive disease entering the trial (CR+PR), only 3 have died and only 2 patients have had disease progression. In contrast, of the 26 patients with relapsed or refractory disease at study entry, 9 have died. The overall and progression free survivals of patients with responsive compared with relapsed/refractory disease are shown in Figure 5.

**DISCUSSION**

Conventional chemotherapy for multiple myeloma is not curative. The use of high dose myeloablative conditioning with autologous stem cell rescue has been associated with greater disease reduction and prolonged disease free and overall survival compared with conventional therapy. In the IFM 90 trial, 38% of patients had a CR (22%) or very good PR with an EFS (median 28 months) at 7 years of 16% and OS (median 57 months) at 7 years of 43%, all superior to conventional chemotherapy. Additional randomized trials have generally favored autografting by demonstrating higher CR rates (22-30%), although EFS and OS are confounded by the salvage use of autologous transplantation in the conventional chemotherapy arms. Autologous transplantation early, rather than as salvage of chemotherapy failure was associated with longer EFS but similar OS. Among a multitude of conditioning regimens, single agent
melphalan (200 mg/m²) has emerged as the current standard by demonstrating the least toxicity with comparable results in patients in good medical condition up to age 70.⁵⁶

The use of tandem high dose regimens with autologous support has been explored by investigators at Arkansas and others.¹²,¹³ The use of the second autograft improved the CR rate from 24% to 43%.⁵⁷ Tandem autografts were superior to conventional chemotherapy in a case-matched analysis with patients treated on Southwest Oncology Group protocols.⁴ Recent analysis of the IFM 94 trial has been presented in abstract form and suggests that tandem autografts are superior to a single autograft with median EFS 37 vs 31 months, 7-year EFS 20% vs 10% and 7-year OS 42% vs 21% respectively.⁵ Surprisingly, there was not an increase in CR rate (35 vs 34%) with the second transplant, and the survival was superior only after 3 years. Despite this aggressive approach, nearly all patients eventually relapse or progress either from the re-infusion of tumor cells contaminating the PBSC or from resistant cells remaining in the patient.

In contrast, the use of allogeneic stem cell support provides a tumor free stem cell source and graft-vs-tumor immune effects. High-dose conditioning and allogeneic HCT has been associated with a high TRM in most trials and led to the premature closure of the allogeneic transplant arm of the North American Trial (TRM ~40%). Overall 6 month TRM has ranged from 21-60%.³⁶-⁴⁰ Analysis of EBMT data base suggests that TRM has decreased in recent cohorts due to better patient selection resulting in decreased infectious and pulmonary toxicity.³⁹ However, the 6 month TRM was still 21% with a 2 year TRM of 30% in patients a median age of 44 (oldest patient age 57). Overall, allogeneic HCT has been associated with a higher rate of molecular remission, but this advantage has been offset by the higher TRM when comparisons are made to single or tandem autologous HCT.

The current study employed a non-myeloablative HCT regimen that reduces treatment related toxicities and shifts the burden of tumor eradication toward the donor’s T-lymphocytes. In order to increase the likelihood of tumor eradication, the patients' disease was first reduced with high-dose melphalan and autologous HCT.
These results allowed the following observations. First, mortalities not related to relapse were 2% with autologous and 15% with allogeneic HCT. The 100-day transplant-related mortality after the allografts was 0%. Second, hematopoietic toxicities were greater following autologous compared to allogeneic HCT. Pancytopenias after non-myeloablative allografts were minimal with both RBC and platelet transfusion requirements reduced compared to conventional grafts. Only 30% of patients had neutrophil nadirs of <500 cells/µL and only 8% of patients had platelet nadirs <50,000/µL. Modest, reversible renal and hepatic toxicities were likely due to high targeted CSP levels to facilitate engraftment.

Third, rapid, sustained allogeneic engraftment occurred. All but one patient had complete donor hematopoietic chimerism by day 84. That patient converted to complete donor chimerism with DLI. This rapid, uniform engraftment contrasts to a non-fatal rejection rate of 18% with the same regimen in patients without preceding autologous HCT. Although the protocol was originally conceived as establishing mixed donor chimerism that would serve as a platform for scheduled DLI to convert from partial to full donor chimerism and treat persistent disease, we observed high donor chimerism, often in the setting of GVHD, precluding the need of DLI in all but one patient.

Fourth, grade II-IV acute GVHD was seen in 39% of patients. Severe disease was only seen in 4 patients (1 grade III, 3 grade IV). Three patients died from complications associated with acute GVHD or its treatment. In the initial phases of this study, CSP was discontinued by day 35. We observed that the median onset of GVHD was 72 days after HCT, and only one patient developed GVHD while treated with both MMF and CSP. These observations have led us to extend CSP in subsequent patients through day 56 with a taper to day 80 or 180 depending on disease activity. Chronic GVHD requiring immunosuppressive therapy occurred in 46% of patients, and three patients have died from late complications resulting from pulmonary complications. Longer follow-up to assess the potential impact of chronic GVHD on outcome, either improved relapse-free survival or increased mortality, is still needed. Thus, while extending one or both of the immunosuppressive drugs may reduce GVHD, their effects on tumor responses will need to be determined. The incidence of GVHD in this study appears similar to standard allografts. Recent comparison of age matched patients treated with
conventional allografts vs nonmyeloablative allografts at our institution found lower grade III/IV acute GVHD (14% vs 38%) but similar chronic GVHD rates in the nonmyeloablative group.59

Finally, 81% of patients showed tumor responses with 52% achieving CR, and 29% PR. This is noteworthy as 48% of patients had relapsed or refractory disease before HCT. Separation of the anti-tumor effects due to the high-dose therapy before autologous HCT and those due to the allografts is difficult, and this issue can only be addressed in future prospective studies. We observed that the median time to CR after allogeneic HCT was 180 (range 100-730) days, consistent with gradual graft-vs.-myeloma effects. Conceivably, patients currently in PR may ultimately achieve CR owing to these effects. Interestingly, five patients had CR within 9 months of allografting without any GVHD, suggesting subclinical graft-vs-host effects or other antitumor effects of this approach may control myeloma. Other patients achieved CR only after GVHD became symptomatic. The durability of the CRs observed is still unknown given that the longest follow-up is only approximately 3 years. To date, only 2 CR patients have had disease progression, however longer follow-up is necessary.

Our approach compares favorably with other recent reports. Badros et al. treated 25 patients with intermediate dose melphalan (100 g/m²) following one or two prior autografts using matched sibling HCT.32,60,61 Six additional patients received fludarabine/TBI and URD grafts. Overall 58% developed acute GVHD and 61% a CR or near CR. Median OS was 15 months and better in patients who received the allograft as planned consolidation of a single autograft. Kröger et al. have also utilized planned tandem auto/allografts using unrelated or mismatched related donors and conditioning with fludarabine, melphalan and antithymocyte globulin in 17 patients.62,63 Day 100 TRM was 11%, and at a median follow-up post allografting of 13 months, the estimated 24 month OS was 74% and disease-free survival 56%. Giralt et al. reported on the use of reduced intensity conditioning with fludarabine and melphalan (140-180 mg/m²) in 22 myeloma patients with advanced disease. Nine had failed prior autologous transplantation. Non-relapse mortality was 19% at 100 days and 40% at 1 year. Survival at 2 years was estimated to be 30% with progression-free survival of 19%.64
In conclusion, we have demonstrated in patients with myeloma the feasibility of combining autologous HCT after high-dose melphalan with non-myeloablative allogeneic HCT. With no treatment-related deaths in the first 100 days after allografting, near complete donor engraftment in all patients, and 81% responses, 52% of which were complete, this procedure appeared to have improved upon the current 20% early transplant-related mortality seen in standard allogeneic HCT for younger patients with multiple myeloma, while maintaining potent anti-tumor effects and allowing allografting in patients up to age 65-70. We plan to compare this approach with tandem autografting for patients without HLA-matched sibling donors in a clinical trial in the Bone Marrow Transplant-Clinical Trials Network (BMT CTN). Patient selection may be critical as we and others have noted increased toxicity in relapsed and refractory patients. The BMT-CTN trial will enroll patients within 3-9 months from initiation of their first chemotherapy. Lastly, based on these encouraging results, the use of autologous transplantation as cytoreduction for nonmyeloablative allografting may be an attractive approach to other malignancies such as advanced lymphoma.

Acknowledgments: Our thanks to the nurses and staff for caring for the patients and for the research nurses, laboratory personnel, secretarial staff and data coordinators, in particular, Debbie Bassuk, who helped capture the study information and follow-up, and Marie-Tère Little, PhD, for chimerism data.
REFERENCES


Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma


Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.